Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCZ | Q05513 | 9/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 1.00 |
| ▸ | HPGD | P15428 | 6/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.76 |
| ▸ | MAPT | P10636 | 5/20 | 0.76 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.76 |
| ▸ | TSHR | P16473 | 2/20 | 0.76 |
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | RECQL | P46063 | 1/20 | 0.67 |
| ▸ | GRM6 | O15303 | 1/20 | 0.55 |
| ▸ | GRM5 | P41594 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | PRKCI | P41743 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1798926 | 0.85 | PRKCZ (0.74) | PRKCZALDH1A1HPGDLMNAMEN1 | |
| SCHEMBL2182710 | 0.85 | PRKCZ (1.00) | PRKCZALDH1A1HPGDLMNAMEN1 | |
| SCHEMBL8288639 | 0.85 | ALDH1A1 (0.76) | PRKCZALDH1A1HPGDLMNAMEN1 | |
| SCHEMBL3995640 | 0.85 | ALDH1A1 (0.76) | PRKCZALDH1A1HPGDLMNAMEN1 | |
| SCHEMBL3932115 | 0.85 | ALDH1A1 (0.76) | PRKCZALDH1A1HPGDLMNAMEN1 | |
| SCHEMBL1190649 | 0.84 | PRKCZ (0.80) | PRKCZALDH1A1HPGDLMNAMEN1 | |
| SCHEMBL5322173 | 0.83 | ALDH1A1 (1.00) | PRKCZALDH1A1HPGDLMNAMEN1 | |
| SCHEMBL26038507 | 0.82 | PRKCZ (0.69) | PRKCZALDH1A1HPGDLMNAMEN1 | |
| SCHEMBL1799330 | 0.82 | KMT2A (0.69) | PRKCZALDH1A1HPGDLMNAMEN1 | |
| SCHEMBL3942905 | 0.81 | PRKCZ (0.68) | PRKCZALDH1A1HPGDLMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122054815-A | Optical repair type perovskite photoelectric device and performance repair method thereof | 中核光电科技(上海)有限公司 | 2026-05-15 | — | — | CN | claimed |
| CN-122054815-A | Optical repair type perovskite photoelectric device and performance repair method thereof | 中核光电科技(上海)有限公司 | 2026-05-15 | — | — | CN | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250296938-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | SHY Therapeutics LLC (US) | 2025-09-25 | — | — | US | disclosed |
| US-12391705-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY THERAPEUTICS, LLC (US) | 2025-08-19 | — | — | US | disclosed |
| US-20240309015-A1 | Methods for the Treatment of Fibrotic Disease | SHY THERAPEUTICS, LLC | 2024-09-19 | — | — | US | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-20240124483-A1 | Methods for the Treatment of Fibrotic Disease | SHY THERAPEUTICS, LLC | 2024-04-18 | — | — | US | disclosed |
| EP-4284377-A1 | METHODS FOR THE TREATMENT OF FIBROTIC DISEASE | Shy Therapeutics LLC (US) | 2023-12-06 | — | — | EP | disclosed |
| US-20230227466-A1 | SUBSTITUTED THIENOPYRIMIDINES THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY THERAPEUTICS, LLC | 2023-07-20 | — | — | US | disclosed |
| US-20120302561-A1 | Compounds, Formulations, and Methods of Protein Kinase C Inhibition | THE PENN STATE RESEARCH FOUNDATION (US) | 2012-11-29 | — | — | US | disclosed |
| US-20120302561-A1 | Compounds, Formulations, and Methods of Protein Kinase C Inhibition | THE PENN STATE RESEARCH FOUNDATION (US) | 2012-11-29 | — | — | US | disclosed |
| WO-2012149452-A1 | COMPOUNDS, FORMULATIONS, AND METHODS OF PROTEIN KINASE C INHIBITION | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-11-01 | — | — | WO | disclosed |
| EP-1953148-B1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-7915267-B2 | Heterocyclic amide compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-29 | — | — | US | disclosed |
| US-20090137603-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-1953148-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007102679-A1 | NOVEL THIENOPYRIMIDINE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | JE IL PHARMACEUTICAL CO., LTD. (KR) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007102679-A1 | NOVEL THIENOPYRIMIDINE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | JE IL PHARMACEUTICAL CO., LTD. (KR) | 2007-09-13 | — | — | WO | disclosed |
| WO-2005033102-A2 | THIOPHENE-BASED COMPOUNDS EXHIBITING ATP-UTILIZING ENZYME INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | AMPHORA DISCOVERY CORPORATION (US) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124483-A1 | Methods for the Treatment of Fibrotic Disease | SMAD3, SMAD2, MAPK3 | PRKCZ 616/4885ALDH1A1 2143/4885HPGD 2101/4885 |
| US-12391705-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | PRKCZ 1452/4885ALDH1A1 3359/4885HPGD 2093/4885 |
| US-20230227466-A1 | SUBSTITUTED THIENOPYRIMIDINES THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | KRAS, G3BP1, NRAS | PRKCZ 1553/4885ALDH1A1 2378/4885HPGD 1303/4885 |
| US-20250296938-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | HRAS, KRAS, NRAS | PRKCZ 1452/4885ALDH1A1 3359/4885HPGD 2093/4885 |
| US-20120302561-A1 | Compounds, Formulations, and Methods of Protein Kinase C Inhibition | PRKCA, PRKCH, PRKCI | PRKCZ 5/4885ALDH1A1 4665/4885HPGD 3541/4885 |
| US-20090137603-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | MMP2, MMP9, MMP1 | PRKCZ 4810/4885ALDH1A1 423/4885HPGD 131/4885 |
| US-20240309015-A1 | Methods for the Treatment of Fibrotic Disease | SMAD3, SMAD2, MAPK3 | PRKCZ 548/4885ALDH1A1 1929/4885HPGD 2014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.